Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)

**Lucinda Bateman**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Fabric Genomics formerly known as Omicia: Value cannot be readily determined
  - **Employment:**
    - Fabric Genomics formerly known as Omicia
  - **Equity Interest:**
    - The investigator has a significant financial interest in Bateman Home Health Center for Excellence, where electronic records will be obtained from in the study.

**Michael Kay**
- **Title and Role:** Data Analyst
- **Description of Conflict:**
  - **Intellectual Property:**
    - Linking Technology: Value cannot be readily determined
  - **Employment:**
    - Linking Technology

**Michael Tanana**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Omicia: Value cannot be readily determined
  - **Employment:**
    - Omicia
  - **Equity Interest:**
    - The investigator has a significant financial interest in Omicia.

**James Hotaling**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Synthetic Biodesign: Value cannot be readily determined
  - **Employment:**
    - Synthetic Biodesign

**K-T Varley**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Frameshift Labs: Value cannot be readily determined
  - **Employment:**
    - Frameshift Labs
  - **Equity Interest:**
    - The investigator has an equity interest in Frameshift Labs, a biotech company which will be commercializing the research. The investigator has a significant financial interest in the licensing company.

**Jeremy Gililland**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - IDbyDNA: Value cannot be readily determined
  - **Employment:**
    - IDbyDNA
  - **Equity Interest:**
    - The investigator has a significant financial interest in IDbyDNA, a non-publicly traded company that will partner with the Varley Lab at University of Utah to conduct this research. The investigator has an equity interest in the licensing company.

**Robert Schlabeg**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Fabric Genomics formerly known as Omicia: Value cannot be readily determined
  - **Employment:**
    - Fabric Genomics formerly known as Omicia
  - **Equity Interest:**
    - The investigator has a significant financial interest in Bateman Home Health Center for Excellence, where electronic records will be obtained from in the study.

**Jenny Gilliland**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - IDbyDNA: Value cannot be readily determined
  - **Employment:**
    - IDbyDNA

**Robert Schlabeg**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Synthetic Biodesign: Value cannot be readily determined
  - **Employment:**
    - Synthetic Biodesign

**B. Varley**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Frameshift Labs: Value cannot be readily determined
  - **Employment:**
    - Frameshift Labs
  - **Equity Interest:**
    - The investigator has an equity interest in Frameshift Labs, a biotech company which will be commercializing the research. The investigator has a significant financial interest in the licensing company.

**Eric Gutfib**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Synthetic Biodesign: Value cannot be readily determined
  - **Employment:**
    - Synthetic Biodesign

**Heather Holman**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - IDbyDNA: Value cannot be readily determined
  - **Employment:**
    - IDbyDNA
  - **Equity Interest:**
    - The investigator has a significant financial interest in the licensing company.

**Mark Kowal**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - IDbyDNA: Value cannot be readily determined
  - **Employment:**
    - IDbyDNA

**M. J. A. Barlow**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - OrthoGrid: Value cannot be readily determined
  - **Employment:**
    - OrthoGrid
  - **Equity Interest:**
    - The investigator has a significant financial interest in OrthoGrid, the study sponsor and manufacturer of the investigational device used in this study.

**Andrew Schlabeg**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Synthetic Biodesign: Value cannot be readily determined
  - **Employment:**
    - Synthetic Biodesign

**Anne Blaschke**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Andro360: Value cannot be readily determined
  - **Employment:**
    - Andro360
  - **Equity Interest:**
    - The investigator has a significant financial interest in Andro360, the company in which the investigator has significant equity interest.

**Jeremy Gililland**
- **Title and Role:** Principal Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Or-Grid: Value cannot be readily determined
  - **Employment:**
    - Or-Grid

**Kailos Genetics**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Kailos Genetics: Value cannot be readily determined
  - **Employment:**
    - Kailos Genetics
  - **Equity Interest:**
    - The investigator has significant financial interest (employment, remuneration and equity interest) in Kailos Genetics, a non-publicly traded company which will be commercializing the research. The investigator has a significant equity interest in Kailos Genetics.

**OntiTec**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Navigen: Value cannot be readily determined
  - **Employment:**
    - Navigen
  - **Equity Interest:**
    - The investigator has a significant financial interest in Navigen, a company in which the investigator has significant equity interest.

**InforBior Technologies**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - InforBior Technologies: Value cannot be readily determined
  - **Employment:**
    - InforBior Technologies
  - **Equity Interest:**
    - The investigator has a significant financial interest in InforBior Technologies, a company in which the investigator has significant equity interest.

**Kailos Genetics**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Kailos Genetics: Value cannot be readily determined
  - **Employment:**
    - Kailos Genetics
  - **Equity Interest:**
    - The investigator has significant financial interest (employment, remuneration and equity interest) in Kailos Genetics, a non-publicly traded company which will be commercializing the research. The investigator has a significant equity interest in Kailos Genetics.

**IDbyDNA**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - IDbyDNA: Value cannot be readily determined
  - **Employment:**
    - IDbyDNA

**Omicia**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Omicia: Value cannot be readily determined
  - **Employment:**
    - Omicia

**Synthetic Biodesign**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Synthetic Biodesign: Value cannot be readily determined
  - **Employment:**
    - Synthetic Biodesign

**Stemline**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Stemline: Value cannot be readily determined
  - **Employment:**
    - Stemline

**Stemline**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Stemline: Value cannot be readily determined
  - **Employment:**
    - Stemline

**GenomeQuest**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - GenomeQuest: Value cannot be readily determined
  - **Employment:**
    - GenomeQuest

**Fabric Genomics**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Fabric Genomics: Value cannot be readily determined
  - **Employment:**
    - Fabric Genomics

**Synthetic Biodesign**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Synthetic Biodesign: Value cannot be readily determined
  - **Employment:**
    - Synthetic Biodesign

**Stemline**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Stemline: Value cannot be readily determined
  - **Employment:**
    - Stemline

**Stemline**
- **Title and Role:** Co-Investigator
- **Description of Conflict:**
  - **Intellectual Property:**
    - Stemline: Value cannot be readily determined
  - **Employment:**
    - Stemline
CRV_00069196  Mark Yandell  Principal Investigator  39,000-59,999  IRB_00021080  Genetics Of Autism

CRV_00068846  T. VAVERK  Co-Investigator  5,000-9,999  IRB_00084861  HEART DISEASE GENETIC NETWORK STUDY (CHD GENES)

CRV_00069608  Robert Tashjian  Principal Investigator  100,000-300,000  IRB_00103100  PEDIATRIC CARDIAC GENOMICS CONSORTIUM: CONGENITAL HEART DISEASE GENETIC NETWORK STUDY (CHD GENES)

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00099871  procedure volume, and safety.

CRV_00069090  Mark Yandell  Principal Investigator  5,000-9,999  IRB_00011203  Arthroplasty

CRV_00068837  E. VANDY  Co-Investigator  5,000-9,999  IRB_00065564  The Role of Ceramides in Skeletal Muscle

CRV_00069196  Mark Yandell  Principal Investigator  0  IRB_00021080  GENETIC EPIDEMIOLOGY OF BREAST CANCER

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  Validation and translation of a non-invasive, MR-guided breast cancer procedure volume, and safety.

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  Validation and translation of a non-invasive, MR-guided breast cancer

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  The Role of Ceramides in Skeletal Muscle

CRV_00069196  Mark Yandell  Principal Investigator  0  IRB_00021080  GENETIC EPIDEMIOLOGY OF BREAST CANCER

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  Validation and translation of a non-invasive, MR-guided breast cancer procedure volume, and safety.

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  Validation and translation of a non-invasive, MR-guided breast cancer

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  Validation and translation of a non-invasive, MR-guided breast cancer

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  Validation and translation of a non-invasive, MR-guided breast cancer

CRV_00069028  Mark Yandell  Principal Investigator  0  IRB_00021080  Validation and translation of a non-invasive, MR-guided breast cancer
# Individual Conflict of Interest Public Disclosures as of June 2, 2023

<table>
<thead>
<tr>
<th>Title and Role</th>
<th>Name</th>
<th>Description of Conflict</th>
<th>Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest</th>
<th>University’s Identification of a New Financial Conflict of Interest</th>
<th>Remuneration</th>
<th>Remuneration Name</th>
<th>Remuneration Value</th>
</tr>
</thead>
</table>

## Mark Yandell

### Principal Investigator

1. **Nonessential measurements of renal perfusion during cardiac surgery**
   - The investigator's licensed intellectual property will be used in the study. The investigator has a significant financial interest in the licensing company.
   - **Value cannot be readily determined**

2. **A novel approach for the selective inhibition of HIF-2α in kidney cancer**
   - The investigator has a significant financial interest in the study. The investigator has a significant financial interest in the licensing company which will provide some test compounds for use in the study.
   - **Value cannot be readily determined**

3. **Nonessential measurements of renal perfusion during cardiac surgery**
   - The investigator's intellectual property will be used in the study. The investigator has a significant financial interest with 3Helix, a company that is commercializing the collagen hybridizing peptide used in this project.
   - **Value cannot be readily determined**

4. **Familial kinship analysis in patients with Mullerian anomalies**
   - The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.
   - **Value cannot be readily determined**

5. **Endometriosis: Natural History, Diagnosis, and Outcomes**
   - The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.
   - **Value cannot be readily determined**

6. **The Hemocompatibility Study of Silica Nanoparticles as a Function of Size and Surface Properties**
   - The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.
   - **Value cannot be readily determined**

7. **INTRAOPERATIVE DATA COLLECTION FOR THE USE OF A NOVEL BREATH SENSOR FOR RAPID, LOW-COST DIAGNOSIS OF TUBERCULOSIS IN CHILDREN**
   - The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.
   - **Value cannot be readily determined**

8. **Pain, Reproductive outcomes (time to pregnancy, prematurity, postpartum depression, etc.), Inheritance patterns (to endometriosis ov or multiple entities), Noise Tests (serotonin and dopamine), Sol Badger Therapeutics, a non-publicly traded company which will allow access to samples from this tissue bank for research.**
   - The investigator has a significant financial interest in the Sol Badger Therapeutics, a non-publicly traded company.
   - **Value cannot be readily determined**

## Philip Bernard

### Co-Investigator

1. **A feasibility study for the early detection of pancreatic cancer**
   - The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.
   - **Value cannot be readily determined**

## Karen Eilbeck

### Co-Investigator

1. **A NOVEL BIOMARKER-BASED THERAPEUTIC FOR CHRONIC BRONCHITIS**
   - The investigator has a significant financial interest in the study. The investigator has a significant financial interest with IDbyDNA; Fabric Genomics formerly known as Omicia.
   - **Value cannot be readily determined**

## Mei Yee Koh

### Co-Investigator

1. **GENETIC EPIDEMIOLOGY OF BREAST CANCER**
   - The investigator has a significant financial interest in the study. The investigator has a significant financial interest with ThermoFisher Scientific Technologies.
   - **Value cannot be readily determined**

## Natalie Silverton

### Co-Investigator

1. **EVALUATION OF A NOVEL BREATH SENSOR FOR RAPID, LOW-COST DIAGNOSIS OF TUBERCULOSIS IN CHILDREN**
   - The investigator has a significant financial interest in the study. The investigator has a significant financial interest with Bioclassifier, LLC.
   - **Value cannot be readily determined**
| CRV_00077257 | Gerald Kroeger | Co-Investigator | 92-30198061 | CKC Medical - A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Barkidin in Adult Patients with Moderate to Severe Acute Dermatitis. | The investigator reports significant financial interest in CKC Medical, the sponsor of the study. | yes | CKC Medical | 122,000-13,000 | no |
| CRV_00077279 | Karen Elbeck | Co-Investigator | 92-30244068 | Utah Market of Risk: Endometriosis (MIRRA) A Longitudinal Sample Collection Study | The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company. | yes | DCGNA | 262,001 to 179,500 | no |
| CRV_00077279 | Mark Yeudell | Principal Investigator | 92-30244068 | Utah Market of Risk: Endometriosis (MIRRA) A Longitudinal Sample Collection Study | The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company. | yes | DCGNA | 262,001 to 179,500 | no |
| CRV_00078080 | Allison Faunce | Principal Investigator | 92-31145606 | Validation of a Protocol for a Non-Invasive, Magnetic Resonance Guided Breast Cancer Therapy | The investigator's licensed intellectual property will be evaluated in the study. | no | no | no |
| CRV_00078495 | Austin Parker | Co-Investigator | 92-31145606 | Validation of a Protocol for a Non-Invasive, Magnetic Resonance Guided Breast Cancer Therapy | The investigator's licensed intellectual property will be used in this project. | no | no | no |
| CRV_00079408 | Robert Schabel | Co-Investigator | 92-30094559 | Genetic and Pharmacogenomic Research Studies Using Archived Glass Slides and/or Formalin-fixed paraffin- embedded Tissue for Additional Testing | The investigator reports a significant financial interest in Biosign, the sponsor of the study. | no | Biosign | 5,000-9,999 | no |
| CRV_00075953 | Ben Delwiche | Co-Investigator | 92-30094559 | Interactive Multimedia Diversion Device with Breath Control | The investigator reports a significant financial interest in Hypnoscure, the sponsor of the project. | no | Hypnoscure | Value cannot be readily determined | no |
| CRV_00075599 | Adrian Bandier | Co-Investigator | 92-30114788 | Isolation of stable LGRADB fibers for population management of FM-afflicted sleep apnea patients through sleep coordinators. | The investigator reports a significant equity interest in Hypnoscure, who manufacturers the device being studied. The investigator’s intellectual property is being used in this project. | yes | no |
| CRV_00079867 | Eric Kaplan | Co-Investigator | 92-30144661 | TRANSMART: Acute Left Atrial Appendage Closure: Randomized Controlled Trial | The investigator has a significant financial interest in the Card-Code Medical, the sponsor of the study. | no | Card-Code Medical | 10,000-19,999 | no |
| CRV_00083836 | Christopher Peters | Co-Investigator | 92-31136386 | Prospective Multicenter, Longitudinal Cohort Study of the Implantability of AnchorPro | The investigator reports a significant financial interest in Zimmer Biomet, the study sponsor. | no | Zimmer Biomet | 242,001 to 30,000 | no |
| CRV_00085458 | Steve Holovack | Co-Investigator | 92-30049446 | LOCALIZED DELIVERY OF GENE THERAPY BY VIRUS FOR THE TREATMENT OF HEPATITIS B INFECTION: AN EXCITED MULTIPLIER | The investigator reports a significant financial interest with Gilead Technologies, whose technology will be used in the project. The investigator is also an inventor of the technology licensed to Gilead. | no | Gilead Technologies | Value cannot be readily determined | no |
| CRV_00088095 | Mark Yavaskal | Co-Investigator | 92-30055458 | Large scale study of prognostic and predictive factors in advanced ovarian cancer | The investigator’s licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company. | no | no |
| CRV_00080690 | Alexander Pantuck | Principal Investigator | 92-30108399 | CYCLOX: DUID AND REPRODUCTIVE HEALTH FELLOWSHIP | The investigator reports a significant financial interest in Exito Pharmaceuticals, the sponsor of the project. | yes | Exito Pharmaceuticals | 10,000-19,999 | no |
| CRV_00080692 | Florian Sabatier | Principal Investigator | 92-30157553 | DEVELOPMENT AND TRANSLATION OF AN INTRACAVAL- AORTIC VENO-VENOUS IMPLANT | The investigator reports a significant financial interest in Blackrock Medical, the study sponsor. The investigator’s intellectual property will be used in this project. | no | Blackrock Medical | $100,000 | no |
| CRV_00087970 | Scott Silver | Co-Investigator | 92-30013444 | OBSTETRICAL DELIVERY IS REFLECTED IN BIRTH OUTCOME | The investigator reports a significant financial interest in Catalysis Therapeutics, the sponsor of the project. | yes | Catalysis Therapeutics | $10,001 to 99,999 | no |
| CRV_00088046 | Joshua Schiffman | Co-Investigator | 92-30127015 | TREATMENT OF OPHTHALMIC DISEASES BY RETINAL VASCULAR THERAPY | The investigator reports a significant financial interest in Peis Therapeutics, the sponsor of the project. The investigator’s intellectual property will be used in this project. | yes | Peis Therapeutics | 10,000-19,999 | no |
| CRV_00088088 | Florian Sabatier | Principal Investigator | 92-30083351 | TRANSMAG: Translational-Based Sitemen to Explore Extracellular Fluid Dynamics | The investigator's intellectual property, licensed to Blackrock Microsystems (a company in which the investigator has a significant financial interest), will be used in the research. | no | Blackrock Microsystems | $100,000 | no |
| CRV_00088089 | Mark Yavaskal | Principal Investigator | 92-30074897 | A Pilot Study of Discovery-Driven Big Data Science: Empowering Evidence-Based Research to Improve the Value of Pediatric Cardiovascular Care | The investigator reports a significant financial interest in the licensing company. The investigator’s intellectual property is being used in this project. | no | no |
| CRV_00088257 | Eric Rust | Co-Investigator | 92-30104809 | Interactive Multimedia Ultrasound Device with Breath Control | The investigator reports a significant financial interest in CJC Medical, who manufactures the device being studied. The investigator’s intellectual property is being used in this project. | yes | CJC Medical | Value cannot be readily determined | no |
| CRV_00088485 | Vera Chon | Co-Investigator | 92-30104809 | Interactive Multimedia Ultrasound Device with Breath Control | The investigator reports a significant financial interest in CJC Medical, who manufactures the device being studied. | yes | CJC Medical | Value cannot be readily determined | no |

**Note:** The table above represents a portion of the data related to financial conflicts of interest as of June 2, 2023. The information includes the names of investigators, their roles, and details about the financial interests associated with their research projects. The table also includes information about the financial value and intellectual property related to the research. The data is organized in a structured format to facilitate easier reading and analysis.
<p>| CRV_00115360 | James Hattung | Co-Investigator | 000132 | JURM SAMPLE PREPARATION FOR FORT OF CARE APPLICATIONS | The investigator has a significant financial interest in JURM, the sponsor of the project. The investigator's intellectual property will be used in this project. This intellectual property is licensed by NexMed. | yes | NexMed | Value cannot be readily determined | yes | Value cannot be readily determined |
| CRV_00115358 | Shengjin Feng | Co-Investigator | 90_0092448 | Head and neck cancer susceptibility genes | The investigator's intellectual property will be used in this project. The intellectual property is licensed to ArrayGenetics Corporation. | no | | | no | Value cannot be readily determined |
| CRV_00115340 | Lisa Bronstein | Co-Investigator | 0005614 | OBSERVATIONAL EVALUATION OF THE RELATION OF THE INTRODUCTION OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV-13) ON THE INCIDENCE OF PNEUMONIA IN CHILDREN AND ADOLESCENTS IN ORANGE COUNTY, CALIFORNIA | The investigator reports a significant financial interest in Biofire Diagnostics, LLC. The investigator reports that her intellectual property will be used in this project. | yes | Biofire | 18,000 to 25,000 | no | Value cannot be readily determined |
| CRV_00115332 | Christopher Peters | Co-Investigator | 90_0013732 | Reduction in total hip arthroplasty | The investigator has a significant financial interest in Primary Care Progress, who provides program management services for the project. | no | | | no | Value cannot be readily determined |
| CRV_00115320 | Mark Yankell | Co-Investigator | 90_0012469 | A Clinical Evaluation of the Vanguard XP Bicruciate Knee System Early Intraoperative &amp; Candidacy Assessment | The investigator's licensed intellectual property will be evaluated in this project. | yes | | | yes | Value cannot be readily determined |
| CRV_00115316 | Andrew Garrison | Co-Investigator | 90_0013172 | Rapid Sequencing in Acutely Ill Infants in the NICU | The investigator reports a significant financial interest from Primary Care Progress, who provides program management services for the project. | yes | Primary Care Progress | 120,000 to 150,000 | no | Value cannot be readily determined |
| CRV_00115304 | Anne Blaschke | Co-Investigator | 10024861 | Systematic evaluation of the relation of the introduction of pneumococcal conjugate vaccine (PCV-13) on the incidence of pneumonia in children and adolescents in Orange County, California | The investigator has a significant financial interest in Framedslab Inc., whose tool will be used in this project. The investigator's licensed intellectual property will be used in this project. The intellectual property is licensed to Framedslab Inc. | yes | Framedslab Inc | Over 500,000 | no | Value cannot be readily determined |
| CRV_00115291 | Kevin Moen | Co-Investigator | 90_0013889 | The Irish Nesbitt Project | The investigator has a significant financial interest in Biofire, a company that manufactures a smartphone app that will be used in this study. | yes | Biofire | 20,000 to 30,000 | yes | Value cannot be readily determined |
| CRV_00115284 | Christopher Gregg | Co-Investigator | 90_0013750 | Behavioral factors for health | The investigator has a significant financial interest in Fabrix, a company that manufactures a smartphone app that will be used in this study. | no | | | yes | Value cannot be readily determined |
| CRV_00115283 | Jeremy Gilliland | Co-Investigator | 90_0012775 | Trident II Asbestos Shell Revision Study | The investigator has a significant financial interest in Storyline Health, sponsor of the project. | no | Storyline Health | Value cannot be readily determined | no | Value cannot be readily determined |
| CRV_00115282 | Andrew Hawthorne | Co-Investigator | 90_0014072 | An educational intervention to address barriers to housing among Veterans at Community Health Centers, Inc. in Salt Lake City, UT | The investigator has a significant financial interest in Community Health Centers, Inc., a company that will be involved in the study. | no | Community Health Centers, Inc. | Over 100,000 | no | Value cannot be readily determined |
| CRV_00115281 | Kristen Yost | Co-Investigator | 90_0014185 | Genomics, whose software will be involved in this study. | The investigator has a significant financial interest in Primary Care Progress, who provides program management services for the project. | yes | Primary Care Progress | 120,000 to 150,000 | no | Value cannot be readily determined |
| CRV_00115279 | Kristen Yost | Co-Investigator | 90_0014221 | Rapid Sequencing in Acutely Ill Infants in the NICU | The investigator's licensed intellectual property will be evaluated in this project. The intellectual property is licensed to Fabrix Genomics. | yes | | | yes | Value cannot be readily determined |
| CRV_00115278 | Lisa Bronstein | Co-Investigator | 0005614 | Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G2 Dual Mobility Construct | The investigator's licensed intellectual property will be evaluated in this project. | yes | | | yes | Value cannot be readily determined |
| CRV_00115276 | Christopher Peters | Co-Investigator | 90_0013732 | Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G2 Dual Mobility Construct | The investigator's licensed intellectual property will be evaluated in this project. | yes | | | yes | Value cannot be readily determined |
| CRV_00115274 | Christopher Peters | Co-Investigator | 90_0013732 | Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G2 Dual Mobility Construct | The investigator's licensed intellectual property will be evaluated in this project. | yes | | | yes | Value cannot be readily determined |
| CRV_00115273 | Christopher Peters | Co-Investigator | 90_0013732 | Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G2 Dual Mobility Construct | The investigator's licensed intellectual property will be evaluated in this project. | yes | | | yes | Value cannot be readily determined |
| CRV_00115272 | Christopher Peters | Co-Investigator | 90_0013732 | Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G2 Dual Mobility Construct | The investigator's licensed intellectual property will be evaluated in this project. | yes | | | yes | Value cannot be readily determined |
| CRV_00115270 | Mark Yankell | Co-Investigator | 90_0014185 | Genomics, whose software will be involved in this study. | The investigator has a significant financial interest in Fabric Genomics, a company that manufactures a smartphone app that will be used in this study. | yes | Fabric Genomics | 120,000 to 150,000 | yes | Value cannot be readily determined |
| CRV_00115269 | Lisa Bronstein | Co-Investigator | 0005614 | Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G2 Dual Mobility Construct | The investigator has a significant financial interest in Fabric Genomics, whose software will be involved in this project. The investigator's licensed intellectual property will be involved in this project. The intellectual property is licensed to Fabrix Genomics. | yes | | | yes | Value cannot be readily determined |</p>
<table>
<thead>
<tr>
<th>ID</th>
<th>Discloser Name</th>
<th>Discloser Title</th>
<th>Disclosure Details</th>
<th>University's Identification of a New Financial Conflict of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRV_00127780</td>
<td>Joshua Schiffman</td>
<td>Principal Investigator</td>
<td>The investigator's licensed intellectual property will be used in the study.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00127946</td>
<td>Jill Shea</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Backdrop Health, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00127944</td>
<td>Richard Landward</td>
<td>Co-Investigator</td>
<td>The investigator's licensed intellectual property will be used in this project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00127980</td>
<td>Shaun Mendenhall</td>
<td>Co-Investigator</td>
<td>The investigator reports several intellectual properties that are directly involved in the project. These intellectual properties are licensed to Backdrop Microsystems.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00127946</td>
<td>Alexander Henrie</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Backdrop Health, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00126641</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator’s licensed intellectual property will be used in the study.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00126641</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has significant financial interests (remuneration) in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00125946</td>
<td>Gabor Marth</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00125426</td>
<td>Massoud Tabib-Azar</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00123124</td>
<td>Kerry Kelly</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00121857</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00121119</td>
<td>Henry Kelle</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00118625</td>
<td>Richard Landward</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00118414</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00118187</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Alexander Henrie</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Massoud Tabib-Azar</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Alexander Henrie</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Mark Yandell</td>
<td>Co-Investigator</td>
<td>The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the research.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Tyler Tucker</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
<tr>
<td>CRV_00117509</td>
<td>Christopher Gregg</td>
<td>Principal Investigator</td>
<td>The investigator has a significant financial interest in Framed Health Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)

Updated within all calendar days of the University's identification of a new Financial Conflict of Interest

<table>
<thead>
<tr>
<th>Discloser</th>
<th>conflicted entity</th>
<th>nature of conflict</th>
<th>description of conflict</th>
<th>remuneration</th>
<th>remuneration name</th>
<th>remuneration amount</th>
<th>conflict status</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAN PIERCE</td>
<td>Eliksa</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest in Eliksa. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.</td>
<td>$19,999</td>
<td>Eliksa</td>
<td>$19,999</td>
<td>Yes</td>
</tr>
<tr>
<td>JAN PIERCE</td>
<td>American Academy of Neurology</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in American Academy of Neurology. The podcast is a product of AAN via its journal, AANx. The technology is licensed to True North Behavioral Health.</td>
<td>$99,999</td>
<td>American Academy of Neurology</td>
<td>$99,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Gordon Lemmon</td>
<td>Fabric Genomics; IDbyDNA; Fabric Genomics</td>
<td>Equity</td>
<td>The investigator reports a significant financial interest (equity) in Fabric Genomics, IDbyDNA, and Fabric Genomics. The investigator has a significant financial interest in Fabric Genomics, IDbyDNA, and Fabric Genomics. The investigator reports a significant financial interest in Fabric Genomics, IDbyDNA, and Fabric Genomics. The investigator reports a significant financial interest (equity) in Fabric Genomics, IDbyDNA, and Fabric Genomics.</td>
<td>$99,999</td>
<td>Fabric Genomics; IDbyDNA; Fabric Genomics</td>
<td>$99,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Edward Dudek</td>
<td>Backdrop Health</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Backdrop Health. The investigator reports a significant financial interest in Backdrop Health, IDbyDNA, and Fabric Genomics. The investigator has a significant financial interest in Fabric Genomics, IDbyDNA, and Fabric Genomics.</td>
<td>$19,999</td>
<td>Backdrop Health</td>
<td>$19,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Lisa Gren</td>
<td>Styker</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (remuneration) from Styker, the sponsor of the project.</td>
<td>$19,999</td>
<td>Styker</td>
<td>$19,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Edward Dudek</td>
<td>Backdrop Health</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest in Backdrop Health, IDbyDNA, and Fabric Genomics. The investigator has a significant financial interest in Fabric Genomics, IDbyDNA, and Fabric Genomics.</td>
<td>$99,999</td>
<td>Backdrop Health</td>
<td>$99,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Gordon Lemmon</td>
<td>Elevated, Inc.</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Elevated, Inc. Wellbeing Elevated's intellectual property will be used in this project. This technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.</td>
<td>$99,999</td>
<td>Elevated, Inc.</td>
<td>$99,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Alexander Bocciar</td>
<td>boostMD</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest in boostMD. Commercialization is imminent to boostMD, a non-publicly traded company in which the investigator will hold a significant financial interest.</td>
<td>$10,000 to $19,999</td>
<td>boostMD</td>
<td>$10,000 to $19,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Marvin Moore</td>
<td>Golden Health, IDbyDNA, and Fabric Genomics</td>
<td>Equity</td>
<td>The investigator reports a significant financial interest (equity) in Golden Health, IDbyDNA, and Fabric Genomics. The investigator has a significant financial interest in Fabric Genomics, IDbyDNA, and Fabric Genomics. The investigator reports a significant financial interest in Fabric Genomics, IDbyDNA, and Fabric Genomics. The investigator reports a significant financial interest (equity) in Fabric Genomics, IDbyDNA, and Fabric Genomics.</td>
<td>$99,999</td>
<td>Golden Health, IDbyDNA, and Fabric Genomics</td>
<td>$99,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Lisa Gren</td>
<td>American Academy of Neurology</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in American Academy of Neurology. The podcast is a product of AAN via its journal, AANx. The technology is licensed to True North Behavioral Health.</td>
<td>$100,000 to $199,999</td>
<td>American Academy of Neurology</td>
<td>$100,000 to $199,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Edward Dudek</td>
<td>Backdrop Health</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Backdrop Health. The investigator reports a significant financial interest in Backdrop Health, IDbyDNA, and Fabric Genomics. The investigator has a significant financial interest in Fabric Genomics, IDbyDNA, and Fabric Genomics.</td>
<td>$200,000 to $999,999</td>
<td>Backdrop Health</td>
<td>$200,000 to $999,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Lisa Gren</td>
<td>Styker</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Styker, the sponsor of the project.</td>
<td>$200,000 to $999,999</td>
<td>Styker</td>
<td>$200,000 to $999,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Gordon Lemmon</td>
<td>Elevated, Inc.</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Elevated, Inc. Wellbeing Elevated's intellectual property will be used in this project. This technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.</td>
<td>$200,000 to $999,999</td>
<td>Elevated, Inc.</td>
<td>$200,000 to $999,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Gordon Lemmon</td>
<td>Elevated, Inc.</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Elevated, Inc. Wellbeing Elevated's intellectual property will be used in this project. This technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.</td>
<td>$200,000 to $999,999</td>
<td>Elevated, Inc.</td>
<td>$200,000 to $999,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Gordon Lemmon</td>
<td>Elevated, Inc.</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Elevated, Inc. Wellbeing Elevated's intellectual property will be used in this project. This technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.</td>
<td>$200,000 to $999,999</td>
<td>Elevated, Inc.</td>
<td>$200,000 to $999,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Gordon Lemmon</td>
<td>Elevated, Inc.</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Elevated, Inc. Wellbeing Elevated's intellectual property will be used in this project. This technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.</td>
<td>$200,000 to $999,999</td>
<td>Elevated, Inc.</td>
<td>$200,000 to $999,999</td>
<td>Yes</td>
</tr>
<tr>
<td>Gordon Lemmon</td>
<td>Elevated, Inc.</td>
<td>Remuneration</td>
<td>The investigator reports a significant financial interest (equity) in Elevated, Inc. Wellbeing Elevated's intellectual property will be used in this project. This technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.</td>
<td>$200,000 to $999,999</td>
<td>Elevated, Inc.</td>
<td>$200,000 to $999,999</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)

<table>
<thead>
<tr>
<th>Discloser</th>
<th>Title and Role</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
</tr>
</thead>
</table>

**JAN PIERCE**

- **Co-Investigator**
  - A Randoamed, Double-Blinded, Placebo-Controlled Study to Determine Safety and Feasibility of Using an Acellular Amniotic Fluid Application to Expedite Healing in Chronic Wounds (AFH for Chronic Wounds)
  - The investigator's intellectual property will be used in the study.
  - The investigator reports significant financial interest in Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.

- **Principal Investigator**
  - A Randoamed, Double-Blinded, Placebo-Controlled Study to Treat Ocular Chronic Graft-Versus-Host Disease (GVHD) With Processed Amniotic Fluid (AF) DROPS
  - The investigator's intellectual property will be used in the study.
  - The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR.
  - The investigator's intellectual property being used in the study.

- **Co-Investigator**
  - A Randoamed, Double-Blinded, Placebo-Controlled Study to Treat Ocular Chronic Graft-Versus-Host Disease (GVHD) With Processed Amniotic Fluid (AF) DROPS
  - The investigator reports significant financial interest in Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.

- **Principal Investigator**
  - A Phase 1 Randomized Double-Blind, Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Amniotic Fluid as a Treatment for COVID-19 Patients
  - The investigator's intellectual property will be used in the study.
  - The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR.
  - The investigator's intellectual property being used in the study.

**Eric Garland**

- **Principal Investigator**
  - A Phase 1 Randomized Double-Blind, Placebo-Controlled Study of MUSC R01 NEURAL MECHANISMS MEDIATING APPETITIVE NICOTINE ADDICTION
  - The investigator's intellectual property is being used in the study.
  - The investigator reports significant financial interest in Eliksa.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.

- **Co-Investigator**
  - A Randomized, Double-Blinded, Placebo-Controlled Study to Treat Ocular Chronic Graft-Versus-Host Disease (GVHD) With Processed Amniotic Fluid (AF) DROPS
  - The investigator's intellectual property will be used in the study.
  - The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR.
  - The investigator's intellectual property being used in the study.

- **Principal Investigator**
  - A Randoamed, Double-Blinded, Placebo-Controlled Study to Treat Ocular Chronic Graft-Versus-Host Disease (GVHD) With Processed Amniotic Fluid (AF) DROPS
  - The investigator's intellectual property will be used in the study.
  - The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR.
  - The investigator's intellectual property being used in the study.

**John Phillips**

- **Co-Investigator**
  - SMART LBP: Optimized Multidisciplinary Treatment Programs for Nonspecific Chronic Low Back Pain
  - The investigator reports significant financial interest in Eliksa.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.

- **Principal Investigator**
  - SMART LBP: Optimized Multidisciplinary Treatment Programs for Nonspecific Chronic Low Back Pain
  - The investigator reports significant financial interest in Eliksa.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.

- **Co-Investigator**
  - SMART LBP: Optimized Multidisciplinary Treatment Programs for Nonspecific Chronic Low Back Pain
  - The investigator reports significant financial interest in Eliksa.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.

**John Phillips**

- **Co-Investigator**
  - SMART LBP: Optimized Multidisciplinary Treatment Programs for Nonspecific Chronic Low Back Pain
  - The investigator reports significant financial interest in Eliksa.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.

- **Principal Investigator**
  - SMART LBP: Optimized Multidisciplinary Treatment Programs for Nonspecific Chronic Low Back Pain
  - The investigator reports significant financial interest in Eliksa.
  - Commercialization is imminent to Eliksa, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.
<table>
<thead>
<tr>
<th>CRV_00147619</th>
<th>CRV_00146928</th>
<th>CRV_00146311</th>
<th>CRV_00145848</th>
<th>CRV_00145246</th>
<th>CRV_00143304</th>
<th>CRV_00141458</th>
<th>CRV_00145441</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Eric Garland**
- Co-investigator: Onchocercia Management for Lumber Spine Surgery
- Principal Investigator

**Andrew Zayachkivsky**
- Co-Investigator

**Luke Maese**
- Co-Investigator

**Eric Garland**
- Co-Investigator

**Stephanie Klein**
- Co-Investigator

**Jeremy Gililland**
- Co-Investigator

**Kerry Kelly**
- Co-Investigator

**Mark Yandell**
- Co-Investigator

**JAN PIERCE**
- Discloser

---

**Linked Title**

**Linked ID**

**Principal Investigator**

**Title and Role**

**Problems**

**Linked Remuneration**

**Remuneration Name**

**Amount**

**Equity Value**

**Intellectual Property Value**

**Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest**

**Remuneration Account**

**Equity**

**Equity Name**

**Equity Value**

**Intellectual Property**

**Updated Intellectual Property Value**

---

<table>
<thead>
<tr>
<th>CRV_00145441</th>
<th>CRV_00146928</th>
<th>CRV_00146311</th>
<th>CRV_00145848</th>
<th>CRV_00145246</th>
<th>CRV_00143304</th>
<th>CRV_00141458</th>
<th>CRV_00145441</th>
</tr>
</thead>
<tbody>
<tr>
<td>10058817</td>
<td>10059643</td>
<td>10060076</td>
<td>10059643</td>
<td>10059643</td>
<td>10059643</td>
<td>10059643</td>
<td>10059643</td>
</tr>
<tr>
<td>Problems</td>
<td>Problems</td>
<td>Problems</td>
<td>Problems</td>
<td>Problems</td>
<td>Problems</td>
<td>Problems</td>
<td>Problems</td>
</tr>
<tr>
<td>Behavioral Interventions for Chronic Pain and Opioid Related CHRONIC EPILEPSY MODELS</td>
<td>Behavioral interventions for active duty service members and veterans with chronic pain conditions and opioid related problems</td>
<td>Problems with the intermittent delivery of sensory feedback (Remuneration)</td>
<td>The investigator's intellectual property will be used in the study.</td>
<td>The investigator reports significant financial interest from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.</td>
<td>The investigator reports significant financial interest from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.</td>
<td>The investigator reports significant financial interest from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.</td>
<td>The investigator reports significant financial interest from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
<td>Jazz Pharmaceuticals</td>
</tr>
<tr>
<td>$19,999</td>
<td>$10,000 to $19,999</td>
<td>$5,000 to $19,999</td>
<td>$5,000 to $19,999</td>
<td>$10,000 to $19,999</td>
<td>$5,000 to $19,999</td>
<td>$10,000 to $19,999</td>
<td>$10,000 to $19,999</td>
</tr>
</tbody>
</table>

---

Page 10 of 18
<table>
<thead>
<tr>
<th>ID</th>
<th>Title and Role</th>
<th>Amount</th>
<th>Remuneration</th>
<th>Equity</th>
<th>Intellectual Property</th>
<th>Description of Conflict</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRV_00160030</td>
<td>Patrick Schlaberg</td>
<td>over $100,000</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>The investigator reports a significant financial interest in IDbyDNA, the study. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160060</td>
<td>Allison Gay</td>
<td>$20,000 to $19,999</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>The investigator reports significant financial interest in Quimbee, a non-publicly traded company which is helping to evaluate technology being studied. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160100</td>
<td>Benjamin Sanchez</td>
<td>$9,999</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160150</td>
<td>Bruce Gale</td>
<td>$5,000 to $19,999</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>The investigator reports significant financial interest in Storyline Health, which provides the artificial intelligence platform being used in the study to identify models of cancer patient care.</td>
</tr>
<tr>
<td>CRV_00160300</td>
<td>Eric Garland</td>
<td>$5,000 to $19,999</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest (equity and remuneration) in Blackrock Microsystems Europe and Blackrock Microsystems. The investigator's intellectual property is being used in the study.</td>
</tr>
<tr>
<td>CRV_00160350</td>
<td>Kate Batten</td>
<td>$10,000 to $9,999</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160500</td>
<td>Derek Douda</td>
<td>$5,000 to $19,999</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160600</td>
<td>Christopher Krogg</td>
<td>Value cannot be readily determined</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160700</td>
<td>Juan Carlos Terraiztegui</td>
<td>$10,000 to $9,999</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160800</td>
<td>Florian Schlaber</td>
<td>Value cannot be readily determined</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00160950</td>
<td>Richard Kipps</td>
<td>Value cannot be readily determined</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00161050</td>
<td>Adam Hays</td>
<td>Value cannot be readily determined</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00161100</td>
<td>Charles M. Pegg</td>
<td>Value cannot be readily determined</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00161200</td>
<td>Lindsey Loughlin</td>
<td>Value cannot be readily determined</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
<tr>
<td>CRV_00161300</td>
<td>Chad Trautwein</td>
<td>Value cannot be readily determined</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>The investigator reports significant financial interest in Blackrock Microsystems. The investigator's intellectual property will be used in the study.</td>
</tr>
</tbody>
</table>
### Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)

**Title and Role**

- **Allison Payne**: Co-Investigator
- **Mitchell Wulfman**: Data Analyst
- **J. Robinson Singleton**: Principal Investigator
- **Gabor Marth**: Co-Investigator
- **Alistair Ward**: Co-Investigator
- **Jeremy Gililland**: Principal Investigator
- **Mary Scholand**: Co-Investigator
- **John Ryan**: Principal Investigator
- **James Patten**: Key Personnel

#### Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

<table>
<thead>
<tr>
<th>Investigator</th>
<th>Title and Role</th>
<th>Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Patten</td>
<td>Key Personnel</td>
<td>yes</td>
</tr>
<tr>
<td>Mitchell Wulfman</td>
<td>Data Analyst</td>
<td>yes</td>
</tr>
<tr>
<td>J. Robinson Singleton</td>
<td>Principal Investigator</td>
<td>yes</td>
</tr>
<tr>
<td>Gabor Marth</td>
<td>Co-Investigator</td>
<td>yes</td>
</tr>
<tr>
<td>Alistair Ward</td>
<td>Co-Investigator</td>
<td>yes</td>
</tr>
<tr>
<td>Jeremy Gililland</td>
<td>Principal Investigator</td>
<td>yes</td>
</tr>
<tr>
<td>Mary Scholand</td>
<td>Co-Investigator</td>
<td>yes</td>
</tr>
<tr>
<td>John Ryan</td>
<td>Principal Investigator</td>
<td>no</td>
</tr>
<tr>
<td>James Patten</td>
<td>Key Personnel</td>
<td>no</td>
</tr>
</tbody>
</table>

####与时俱进的科技发展趋势

- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator's intellectual property is being used in the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. They will be collecting publicly available data from the Tetrad Optics, LLC, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator has a significant financial interest in Axon Optics, LLC, who will provide the glasses for the study. The investigator's licensed intellectual property will be used in the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. They will be collecting publicly available data from the Tetrad Optics, LLC, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator has a significant financial interest in Axon Optics, LLC, who will provide the glasses for the study. The investigator's licensed intellectual property will be used in the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. They will be collecting publicly available data from the Tetrad Optics, LLC, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator has a significant financial interest in Axon Optics, LLC, who will provide the glasses for the study. The investigator's licensed intellectual property will be used in the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. They will be collecting publicly available data from the Tetrad Optics, LLC, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator has a significant financial interest in Axon Optics, LLC, who will provide the glasses for the study. The investigator's licensed intellectual property will be used in the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Rebel Medicine, who will provide the glasses for the study.
- **Fabric Genomics**: The investigator's intellectual property is being used in research. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
- **Fabric Genomics**: The investigator's licensed intellectual property is being used in the study. The investigator has a significant financial interest in the study sponsor, Fabric Genomics, the licensor of the technology.
Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)

<table>
<thead>
<tr>
<th>Title of Study</th>
<th>Principal Investigator</th>
<th>Co-investigator</th>
<th>Key Personnel</th>
<th>Description of Conflict</th>
<th>Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest</th>
<th>Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest</th>
<th>Financial Conflict of Interest Value</th>
<th>Intellectual Property Value</th>
<th>Linked Title</th>
<th>Linked ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Study Sponsor</td>
<td>Name</td>
<td>Amount</td>
<td>Equity</td>
<td>Remuneration Name</td>
<td>Remuneration Description</td>
<td>Remuneration Description</td>
<td>Equally</td>
<td>Equity Value</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
</tbody>
</table>
The investigator has a significant financial interest in Sarepta Therapeutics.

The investigator's intellectual property will be used in the study.

The investigator's intellectual property will be used in the project. The investigator reports a significant financial interest in Nanospot.ai, a non-publicly traded company which will be commercializing the technology.

The investigator reports a significant financial interest from the sponsor Bayer.

The investigator reports significant financial interest with the sponsor Depuy Synthes Mitek.

The investigator reports a significant financial interest in Sarepta and the sponsor AltaThera.

The investigator has a significant financial interest in the study.

The investigator's intellectual property is being used in the study.

The investigator's intellectual property is being used in the study.

The investigator reports a significant financial interest in Serono, the manufacturer of study drug Avelumab.

The investigator reports a significant financial interest in BIOS, a non-publicly traded company which will be commercializing the technology.

The investigator's intellectual property will be used in the study.

The investigator reports significant financial interest from the sponsor Serono, the manufacturer of study drug Avelumab.

The investigator reports a significant financial interest in BIOS, a non-publicly traded company which will be commercializing the technology.

The investigator reports a significant financial interest in Biospot MDS.

The investigator reports significant financial interest from the sponsor Bayer.

The investigator reports significant financial interest from the sponsor Bayer.

The investigator reports significant financial interest from the sponsor Bayer.

The investigator reports a significant financial interest in Serono, the manufacturer of study drug Avelumab.
**Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)**

**Eric Garland**
- **Principal Investigator**
- **Conflict of Interest:** Development and use of patient-derived xenograft and organoid models. The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Josef Stehlik**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in Evolution Bio, the licensor of the technology.

**JUSTIN ENGLISH**
- **Principal Investigator**
- **Conflict of Interest:** The investigator reports a significant financial interest in the licensor of the technology.

**Gabor Marth**
- **Principal Investigator**
- **Conflict of Interest:** Equities. The technology has been licensed to Sentiomed, a non-publicly traded company in which the investigator reports a significant financial interest. Sentiomed is a sponsor of this project.

**ALANA WELM**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**David Shields**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in Fabric Sciences, a company which produces tools used in the study.

**ALANA WELM**
- **Principal Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Debra Eckert**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Mark Yandell**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Edward Hernandez**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Michael Ray**
- **Principal Investigator**
- **Conflict of Interest:** The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Debra Eckert**
- **Principal Investigator**
- **Conflict of Interest:** The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Timothy Copeland**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Mark Yandell**
- **Principal Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Michael Ray**
- **Principal Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Debra Eckert**
- **Principal Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**Edward Hernandez**
- **Principal Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**EUNG YEHONG**
- **Co-Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**SUZANNE WHEATLEY**
- **Principal Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.

**JASON ELLISON**
- **Principal Investigator**
- **Conflict of Interest:** Remuneration. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.
<table>
<thead>
<tr>
<th>Title and Role</th>
<th>Number</th>
<th>Amount</th>
<th>Remuneration</th>
<th>Equity Name</th>
<th>Intellectual Property Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mary Scholand</td>
<td>Co-Investigator</td>
<td>$30,000 to $99,999</td>
<td>no</td>
<td>no</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Michael Free</td>
<td>Principal Investigator</td>
<td>$20,000 to $9,999</td>
<td>no</td>
<td>no</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Anna Chalmers</td>
<td>Principal Investigator</td>
<td>$5,000 to $9,999</td>
<td>no</td>
<td>no</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Dennis Parker</td>
<td>Principal Investigator</td>
<td>$5,000 to $99,999</td>
<td>no</td>
<td>no</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Tommaso Lenzi</td>
<td>Principal Investigator</td>
<td>Zero to $4,999</td>
<td>no</td>
<td>no</td>
<td>Value cannot be readily determined</td>
</tr>
</tbody>
</table>

Note: The table above represents a portion of the data from the document. The full table includes additional entries not shown here.
<table>
<thead>
<tr>
<th>Discloser</th>
<th>Remuneration</th>
<th>Intellectual Property Value</th>
<th>Equity Value</th>
<th>Equity Name</th>
<th>Equity Remuneration</th>
<th>Remuneration</th>
<th>Intellectual Property Value</th>
<th>Equity Value</th>
<th>Equity Name</th>
<th>Remuneration</th>
<th>Intellectual Property Value</th>
<th>Equity Value</th>
<th>Equity Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nancy Allen</td>
<td>$39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Anwar Tandar</td>
<td>$39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Frameshift Labs, Inc</td>
<td>Over $100,000</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>broccoli</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Kent Bachus</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Alistair Ward</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Josef Stehlik</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>John Ryan</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Marshall Smith</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Kerry Kelly</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Brook Martin</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Eric Garland</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
<tr>
<td>Nancy Allen</td>
<td>$10,000 to $39,999</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
<td>Value cannot be readily determined</td>
</tr>
</tbody>
</table>

**Description of Conflict**

Updated within 60 calendar days of the University’s identification of a new Financial Conflict of Interest

**Updated**

Updated within the calendar year of the University's identification of a new Financial Conflict of Interest.

**Disclosure**

Disclosure of Financial Conflict of Interest.
Individual Conflict of Interest Public Disclosures as of June 2, 2023 (if required for public disclosure)

**Claude Nanjo**
- **Title and Role**: Principal Investigator
- **Design, Implementation and Evaluation of Scalable Decision Making in Patients with Idiopathic Pulmonary Fibrosis (IPF)**
- **WA42293**: A Phase III Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Sotatercept When Added to Background Pulmonary Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
- **WA42294**: A Phase III Open-Label Extension Study to Evaluate Sotatercept When Added to Background Pulmonary Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
- **Value cannot be readily determined**

**Mary Beth Scholand**
- **Title and Role**: Principal Investigator
- **Principal Investigator**
- **Design, Implementation and Evaluation of Scalable Decision Making in Patients with Idiopathic Pulmonary Fibrosis (IPF)**
- **WA42293**: A Phase III Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Sotatercept When Added to Background Pulmonary Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
- **WA42294**: A Phase III Open-Label Extension Study to Evaluate Sotatercept When Added to Background Pulmonary Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
- **Value cannot be readily determined**

**JAMIE DWYER**
- **Title and Role**: Principal Investigator
- **Principal Investigator**
- **EVALUATING THE EFFICACY AND SAFETY OF BI 1015550 OVER AT LEAST 52 WEEKS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)**
- **Value cannot be readily determined**

**MARK CLEMANN**
- **Title and Role**: Principal Investigator
- **Real-World, Long-Term Data Collection To Gain Clinical Insights To Evaluate CIN-10 For The Treatment Of Patients With Uncontrolled Hypertension And Heart Failure (CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, MACITENTAN IN INOPERABLE OR PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION)**
- **Value cannot be readily determined**

**Kailos Genetics, the licensor of the technology.**
- **The investigator reports a significant financial interest with sponsor Kiniksa Pharmaceuticals.**

**Genentech, the study sponsor and manufacturer.**
- **The investigator reports significant financial interest in sponsor Genentech, the study sponsor.**
- **The investigator reports significant financial interest in sponsor, Boehringer Ingelheim.**
- **The investigator reports significant financial interest in sponsor, AstraZeneca Pharmaceuticals.**

**Roche/Genentech, which is the manufacturer of products used in this project.**
- **The investigator reports significant financial interest in sponsor, Boehringer Ingelheim.**

**Dexcom, Inc**
- **The investigator reports significant financial interest in sponsor, Dexcom, Inc.**
- **The investigator reports a significant financial interest in sponsor, B-Secur.**
- **The investigator reports significant financial interest in sponsor B-Secur.**

**B-Secur**
- **B-Secur**

**Kliniksa**
- **Kliniksa**

**AstraZeneca Pharmaceuticals**
- **AstraZeneca Pharmaceuticals**

**Edilytics, Inc**
- **Edilytics, Inc**

**Intellectual Property Value**
- **Value cannot be readily determined**
- **Value cannot be readily determined**
- **Value cannot be readily determined**

**Equity Value**
- **Value cannot be readily determined**
- **Value cannot be readily determined**
- **Value cannot be readily determined**

**Intellectual Property**
- **Intellectual Property**
- **Intellectual Property**
- **Intellectual Property**

** disclosures in the document.**